Theravance Biopharma (NASDAQ:TBPH - Get Free Report) is expected to release its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect Theravance Biopharma to post earnings of $0.0280 per share and revenue of $17.7830 million for the quarter. Interested persons can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.
Theravance Biopharma Stock Up 1.3%
NASDAQ:TBPH opened at $16.94 on Thursday. Theravance Biopharma has a 12-month low of $8.33 and a 12-month high of $21.03. The firm has a market capitalization of $872.58 million, a PE ratio of 8.34 and a beta of 0.19. The firm has a 50-day moving average price of $15.83 and a 200 day moving average price of $17.35.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on the stock. BTIG Research reaffirmed a "buy" rating and set a $21.00 price objective on shares of Theravance Biopharma in a report on Friday, March 20th. B. Riley Financial raised their price objective on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a "neutral" rating in a report on Tuesday, April 7th. Wall Street Zen lowered shares of Theravance Biopharma from a "strong-buy" rating to a "buy" rating in a report on Saturday, May 2nd. TD Cowen increased their target price on Theravance Biopharma from $13.00 to $15.00 and gave the stock a "hold" rating in a report on Monday, March 23rd. Finally, HC Wainwright increased their target price on Theravance Biopharma from $20.00 to $27.00 and gave the stock a "buy" rating in a report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $21.83.
Read Our Latest Analysis on TBPH
Insider Buying and Selling at Theravance Biopharma
In related news, SVP Rhonda Farnum sold 31,067 shares of the firm's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the sale, the senior vice president owned 232,699 shares of the company's stock, valued at $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 6.90% of the stock is currently owned by corporate insiders.
Institutional Trading of Theravance Biopharma
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of Theravance Biopharma by 2.5% in the third quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company's stock valued at $32,289,000 after purchasing an additional 54,152 shares in the last quarter. State Street Corp increased its holdings in shares of Theravance Biopharma by 4.4% in the fourth quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company's stock valued at $20,616,000 after purchasing an additional 45,987 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Theravance Biopharma by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company's stock valued at $17,567,000 after purchasing an additional 40,734 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Theravance Biopharma by 12.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 858,957 shares of the biopharmaceutical company's stock valued at $16,072,000 after purchasing an additional 92,253 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of Theravance Biopharma in the third quarter valued at approximately $10,611,000. Institutional investors and hedge funds own 99.10% of the company's stock.
About Theravance Biopharma
(
Get Free Report)
Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Theravance Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theravance Biopharma wasn't on the list.
While Theravance Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
